RenovoRx Inc Stock News

September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.

Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board's Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board's Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment ...

MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnost...

MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared drug-delivery device, today announced that it will host its third quarter 2025 financial results and business highlights conference call on November ...

LOS ALTOS, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Sites The PanTheR Study is Gathering Expanded Safety and Performance Data of the FDA-Cleared RenovoCath ® Device and its Associated Survival Outcomes...

MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Fall Inves...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The co...